The CDMO segment of GenScript, a leading biotech company announced that it signed a strategic collaboration agreement with Selecxine Inc., a Korean biotech company dedicated to novel therapeutics for immuno-oncology. The parties have reached a partnership on innovative antibody drug development. According to the agreement, GenScript will be responsible for preclinical pharmacy research and IND filing in Selecxine's project. This project is based on cytokine-antibody complexes. Compared with classic monoclonal antibody and protein drug, this project provides a new insight into new drug development. It is said that the project is challenging, featuring novel design of the drug molecular form. As there are no drugs in the market for reference, this presents a great challenge to GenScript's process development capability. After the comprehensive project evaluation, based upon its extensive experience in biologics process development, GenScript has provided development solutions in different hosts tailored to customers and provided the preparation and purification solutions for the final complex, which won recognition from customers. This project will further test and enhance the process development capability of GenScript CDMO team. "We are delighted to reach strategic collaboration with Selecxine in the field of innovative drug development. In recent years, Korea's biopharmaceutical industry has grown rapidly. Among outstanding innovative biotech companies in Korea, Selecxine has extensive experience in innovative therapeutics," Dr. Brian Min, CEO of GenScript BDBU said, "This collaboration once again demonstrates our superior process development capabilities. We would like to empower more innovative companies like Selecxine in the future to accelerate the development of innovative therapies and new drug approval." Dr. Jun-Young Lee, CEO of Selecxine, said at the signing ceremony, "I am so glad to have a collaboration with global CDMO GenScript to develop our lead candidate SLC-3010. During last several years, we have experienced the capability of GenScript as global CDMO through successful performance on multiple sub-projects belong to SLC-3010. I believe that the newly updated agreement for closer partnership covering wide range of new medicine development processes from stable cell line development to GMP production of SLC-3010 will lead us to clinical trials. I hope to maintain this great business partnership as growing together for developing better out-comes in this promising field of drug development."